Seeking Alpha
 

Medtronic Inc. (MDT)

- NYSE
  • Nov. 6, 2012, 7:38 PM
    Medtronic (MDT) announces interim findings from clinical trials which show that biventricular pacing may offer a significant advantage and improved patient outcomes over conventional right ventricular pacing among pacemaker patients. The findings were presented as a late-breaking clinical trial at the American Heart Association's 2012 Scientific Sessions, and show a 27% relative risk reduction in the composite of death and healthcare utilization visits among patients requiring intravenous heart failure therapy.
    | 1 Comment
  • Nov. 5, 2012, 9:39 AM
    Bypass surgery is more effective than drug-coated stents in preventing heart attacks and deaths in diabetics with more than one diseased artery, a five-year study shows. However, there were more strokes among bypass patients. Still, the data could lead to changes in treatment recommendations for thousands of people, hurting the profits of stent makers such as Abbott Labs (ABT -0.3%), Boston Scientific (BSX) and Medtronic (MDT -0.2%).
    | Comment!
  • Oct. 25, 2012, 3:48 AM
    The integrity of research into Medtronic's (MDT) bone-growth protein Infuse, which is used in spine surgery, has been called into question by a Senate Finance Committee report that says the company was "heavily involved in drafting, editing and shaping the content of medical journal articles" about the product. Medtronics also paid $210M for unrelated work to the doctors who wrote the articles.
    | Comment!
  • Oct. 22, 2012, 9:48 AM
    Medtronic's (MDT +0.2%) CoreValve heart implant increased 1-year survival rates amongst patients in a study and it improved their quality of life. Separately, a trial of the company's Symplicity renal denervation treatment helped reduce blood pressure in patients with "treatment-resistant hypertension," who have a high risk of "various cardiovascular events."
    | Comment!
  • Oct. 3, 2012, 2:12 PM
    Medtronic (MDT +0.3%) says it's successfully completed the first phase of feasibility studies on its next-generation renal denervation system, which features a simultaneously firing multi-electrode catheter and advanced radio-frequency generator. A total of nine patients were treated with a 100% acute success rate in accessing the vessels and delivering therapy. The system is only in its investigational phase however, and isn't yet commercially available anywhere in the world.
    | Comment!
  • Sep. 28, 2012, 12:45 PM
    Midday top 10 gainers: BYFC +171.43%. DHRM +28.21%. CHC +22.24%. KH +21.35%. CYTX +19.17%. CT +18.53%. AZZ +13.84%. NAVR +12.5%. REDF +12.14%. PCYO +11.12%.
    Top 10 Losers: CTC -16.16%. ULTR -12.27%. ASTC -10.26%. ALCS -9.42%. CRVP -9.17%. PPHM -8.86%. ASTI -8.76%. ADTN -8.66%. VSCI -8.57%. IRDM -7.76%.
    | Comment!
  • Sep. 28, 2012, 5:41 AM
    Medtronic (MDT) agrees to pay $816M for China Kanghui, a provider of orthopedic implants in a deal that expands the U.S. company's presence in China. Medtronic's offer of $30.75/ADR represents a 22.5% premium to Kanghui close yesterday. Barclays analyst Jason Mann says Kanghui provides Medtronic with "access to thousands of hospitals...(in) the fastest growing orthopedic market." (PR)
    | Comment!
  • Sep. 26, 2012, 7:56 AM
    The EU proposes tougher standards on medical devices and implants after investigations showed hundreds of thousands of women were at risk from substandard silicone implants. Independent assessment of manufacturers and increased product testing could result from the new legislation.
    | 4 Comments
  • Sep. 18, 2012, 11:58 AM
    An Appeals court has overturned a lower court ruling that found Medtronic (MDT +0.2%) did not infringe on Boston Scientific (BSX -1.4%) CRT patents, and has remanded the case for further proceedings. The appeals court says the lower court relied on a "legally incorrect allocation of the burden of proof" and incorrectly construed the claim terms in the suit.
    | Comment!
  • Aug. 27, 2012, 8:38 AM
    Medtronic's (MDT) Protect study confirms the long-term safety of drug-eluting coronary stents, which slowly release a drug to block cell proliferation. The trial, the largest ever for such products, used Medtronic's Endeavor stent and J&J's (JNJ) Cypher to test for stent thrombosis, when a blood clot forms inside the stent. (PR)
    | 4 Comments
  • Aug. 24, 2012, 1:32 PM
    Medtronic (MDT +0.3%) receives FDA and CE Mark approval for its Arctic Front Advance cardiac cryoballoon for the treatment of paroxysmal atrial fibrillation. MDT has the only cryoballoon system currently on the market worldwide, which is purported to provide a more efficient approach to treating the condition than through point-by-point, radiofrequency ablation.
    | Comment!
  • Aug. 21, 2012, 9:17 AM
    Medtronic's (MDT) business for neuromodulation devices received an FDA warning letter related mainly to the company's processes for handling complaints, MDT CFO Gary Ellis disclosed in a conference call, adding that he does not expect a material impact on financial results. (earlier: FQ1 results)
    | Comment!
  • Aug. 21, 2012, 7:49 AM
    More on Medtronic (MDT -3.1%) FQ1: net profit +5.2% to $864M; net revenues +5% on constant currency basis after adjusting for a $119M negative forex impact. Reiterates FY 2013 EPS guidance of $3.62-$3.70 vs. consensus of $3.66. International revenue +6% and accounts for 44% of the total. Emerging market +14% "Growth was broad-based across businesses and geographies." (PR)
    | Comment!
  • Aug. 21, 2012, 7:20 AM
    Medtronic (MDT): FQ1 EPS of $0.83 misses by $0.02. Revenue of $4B in-line. (PR)
    | Comment!
  • Aug. 21, 2012, 12:05 AM
    Notable earnings before Tuesday’s open: BBY, BKS, MDT, TSL
    | Comment!
  • Aug. 20, 2012, 5:30 PM
    Notable earnings before Tuesday’s open: BBY, BKS, MDT, TSL
    | Comment!
Visit Seeking Alpha's
MDT vs. ETF Alternatives
Company Description
Medtronic PLC is engaged in providing medical technology alleviating pain, restoring health, and extending life of people. It currently functions in three operating segments that manufacture and sell device-based medical therapies.